Bad news they lost $60M rev from the VA in-housing some of their testing. Still have good relationship. Lost revenue will not require layoffs because of how efficient they are. Good news replaced $60M with acquisition, expecting 9% growth overall this year. Moving forward no customer is more than 10% of revenue. Acquisition adds 20-30 sales rep, all sales reps now have cross selling opportunities. Acquisition will be upgraded with digital slide tech.
Not sure that deserves a 30% hit to price well below cash value.
https://ir.fulgentgenetics.com/events/event-details/q4-2025-fulgent-genetics-earnings-conference-call